BioJobBlog Surpasses the 2.0 Million Reader Mark!
.jpg)
I started BioJobBlog in 2007 primarily as a means for me to express myself about life science careers and issue and challenges confronting the biotechnology, pharmaceutical and medical devices industry. That said, I never thought that BioJobBlog would ever amount to much; it was simply a vehicle for me to rant and rave about things that were important to me! It is a daunting challenge to begin a blog with no readers and then realize that 5 years later over 2.0 million unique readers have visited to read my thoughts and ideas about a wide breadth of topics.
I want to thank the readers who continue to visit BioJobBlog. And, I hope that what I have written over the past five years has either helped or induced you to think about issues in the life sciences industry. While I have no plans to stop blogging; my schedule is becoming increasingly challenging and I can no longer post articles as frequently as I have in the past. Nevertheless, I will continue do what I can to keep the content at BioJobBlog interesting, fresh and thought-provoking.
Please feel free to contact me with ideas, thoughts or comments about the blog (or anything else for that matter).
Thanks for supporting BioJobBlog!
Until next time...
Good Luck and Good Job Hunting!!!!!!!!!
.jpg)
Ome Ogbru, Pharm. D, CEO and Founder of 
There are differences of opinions regarding whether or not to include certain things on a resume or curriculum vitae (CV). Some career specialists contend that it is okay to include things like an objective statement, “references upon request”, telephone numbers and hobbies on a CV whereas others do not. That said, most career experts agree that the following SHOULD NOT appear on a resume or CV 
For many corporate employees, the annual performance review process is a bane to their existence. For those of you who may not be familiar with annual reviews, most corporate employees are required to undergo a review process that includes a synopsis of their accomplishments over the past year and new goals for the upcoming one. And, as all corporate employees understand, the quality of an annual review determines the size of the bonus that they can expect to receive and whether or not a salary increase is in order for the upcoming fiscal year. In other words, you never want to get a “less than stellar” annual review because your fiscal well-being depends on it!
There are a variety of reasons why the life sciences job market has been so dismal in recent years. First and foremost, there are too many applicants for too few jobs; employers are ignoring resumes/CVs that previously commanded face-to-face interviews. Second and perhaps more pernicious, is the notion among corporate executives and hiring managers that current graduates (both undergraduate and graduate students) have been catered to and are so academically untested that they bring little or no value to today’s fast-paced and demanding workplaces. While this characterization may or may not be warranted, it is a prevailing attitude that is likely hindering employment opportunities for recent life sciences graduates.(1).jpg)
While China and India have gotten the most attention as emerging pharmaceutical markets, Latin American markets most notably Mexico and Brazil (okay, it is a South American country but it can be included in Latin America) have been quietly expanding as rapidly as the Indian and Chinese markets. To wit, Denmark-based, Novo Nordisk—the world’s largest insulin maker—
I received a heads-up from the American Chemical Society’s (ACS) Sergio Lewis about a free webinar entitled “How to Secure and Nurture a Vibrant Chemistry Career in the 21st Century.” The webinar is scheduled for December 1, 2011 from 2:00-3:00 PM and will be led by Brian Fahie, PhD from Eli Lilly & Co. The presentation will be followed by a Q&A session.
While many of you are happy just because you have a job, there are those individuals (deserving or not) who are going to “bite the bullet” and ask for a raise. This makes sense because over the past few years the cost of health insurance has gone up along with college tuition, gasoline price and a variety of other things while salaries have all but stagnated. Interestingly, only 9 percent of companies have put pay freezes in place over the past 18 months; a rate this is consistent with historical standards. That is down from the nearly two-thirds of companies that imposed pay freezes in January 2010. In other words, now may be a good time to ask for a raise as companies are trying to retain high value employees who presumably were too vital to lay off when companies were downsizing over the past three years. Sadly, merit raises (when they are meted out) have precipitously dropped in recent years from an average of roughly 4-5 percent to a paltry 2 percent on average today.
Most aspiring young scientists tell me that they love doing bench work and that they want to do it for their entire career. I am never certain whether they actually feel that way or they are simply telling me what they think I want to hear. Nevertheless, I want to share my own feelings about bench work because I think it may be instructive for jobseekers who may not be entirely certain about their chosen career paths.
Last week, BioJobBlog in association with .jpeg)
Conventional wisdom suggests that failure or negative comments can be harmful or potentially damaging to the career trajectory of most people. While in many cases this may be true, sometimes they may have an opposite and unanticipated positive effect or benefit. This is certainly true for me.
Times are tough for many in the legal profession these days. However, the demand for patent experts including attorneys and patent agents is skyrocketing. According to an 
According to an.jpg)
Mark Senak, author of the outstanding 
There is no question that the US is lagging behind other nations in science, technology, engineering and math. While this may be troubling to some, Americans possess one skill that provides them with an unheralded advantage; that is entrepreneurship. Entrepreneurial skills cannot be easily taught or learned. And while most Americans don’t know it, entrepreneurship is a passively acquired trait that most non-Americans would “kill for.” Unfortunately, the recent recession and increasing global competition had dampened Americans entrepreneurial enthusiasm to the point where risk-adverse business behavior is threatening to stifle US innovation.
There is no longer any doubt that big pharma companies are beginning to 
Depending upon the source, the cost of bringing a new prescription drug to market these days ranges from roughly $1.2 to 1.5 billion. While there is no question that clinical studies represent the most costly aspect of getting new drugs approved, the hidden costs—mainly promotion and marketing—are what actually inflate the costs of new drug development. Not surprisingly, drugmakers fail to disclose that these costs are included in the estimates for new drug development. If these costs were eliminated from the total, then the cost of developing new drugs will be significantly less than the current $1.2 to $1.5 billion price tag..jpg)
There has been some buzz on LinkedIn and Facebook about an article that appeared in the March 3, 2011 issue of Nature Magazine. The article entitled 
Despite assertions to the contrary, scientists are pretty much like most other people. They eat, sleep, work, party and for the most part are social creatures. Therefore, it should come as no surprise that scientists are also susceptible to hype and succumb to research “fads.” In my former life as an academician, these fads were not so obvious and, for the most part, they unobtrusively helped to advance scientific research. However, after I abandoned academia for the private sector, these fads became blatantly obvious to me. And, for the most part, were primarily driven by potential profits rather than advancing scientific knowledge for the common good..jpg)
Two years ago Merck 
Aptuit, a drug discovery and development company 
While I typically don’t subscribe to practice of unbridled self promotion, I could not pass on the opportunity to let my readers know that BioJobBlog made the "Top 50 Blogs About Careers in Science."
Vincent Racaniello, 
Despite assertions by its CEO that there isn’t enough scientific talent in the US, Eli Lilly announced that it will lay off a couple of thousand employees within the next 90 days. Most of the cuts will take place in Indianapolis at four different sites where the company currently employees about 13,000 workers. According to an
I read a post today on Yahoo News entitled.jpg)
Yesterday, I posted a piece on "hit' throughput screening (see below). At the time, I learned about 'hit" throughput screening, I mentioned that I had never heard of "hit" throughput screening but I did know about high throughput screening. As it turns out, there was a problem in translation and in fact, there is no such thing as hit throughput screening and it is actually high throughput screening. Mea Culpa! I apologize for the error and in the future I will be assiduous in my fact checking before I post (a lesson that the boneheads in the Obama administration learned the hard way in the recent Sherrod brouhaha)
Pfizer’s .jpg)
Pharmaceutical and biotechnology companies like to distinguish themselves from companies that manufacture consumer products because their products have the potential to save the lives of patients suffering from a plethora of illnesses. While a life-saving cancer treatment may inherently be more valuable than a pair of snow tires, the goal of the companies that manufacture them is to sell enough products to remain profitable. To that end, pharmaceutical and biotechnology companies have an edge over consumer products companies because drug makers can use altruism and philanthropy to market their drugs. In fact, many drug manufacturers play up their commitments to altruism and philanthropy to justify high drug prices because of the enormous costs associated with drug discovery and development. This tactic begs the question: “Just how philanthropic are drug makers?”
If you would have asked me that question before I became a professional recruiter and hiring manager, I would have suggested that body language plays a minimal role in the success or failure of a face-to-face job interview or business meeting. However, over the years, I have come to realize that body language is extremely important; and it may be the deciding factor in whether or not a job offer is proffered or a business deal is consummated.
As a career development professional, I frequently offer job seekers tips on how to conduct a successful job search. However, my views on the topic are mainly derived from a five year stint as a professional recruiter and over 20 years as a job seeker. With this in mind, it may helpful for job candidates to hear the other side of the story; that is, what hiring managers expect from job seekers.
I will be at the 
Samantha Miller of the.gif)
We previously announced that .jpg)
For the past decade or more multiple drug resistant strains of bacteria such as methicillin resistant Staphylococcus aureus (MRSA), enterococci and other Gram positive cocci have been highlighted and showcased in the medical and lay press. While the incidence of infections caused by MRSA and other Gram positive cocci has steadily risen, antibacterial drug discovery experts have long known that the greatest disease threat in the future will be from emerging multiple antibiotic resistant strains of Gram negative bacteria including Acinetobacter baumannii, Klebsiella pneumoniae, Serratia marcescens and Pseudomonas aeruginosa..gif)
While I don’t advocate postdoctoral positions for individuals unless they plan on doing bench science for the rest of their lives, postdoctoral training is a fact of life for those interested in pursuing academic careers. To that end, The Scientist.com conducts an annual survey that ranks the .jpg)
A rare or orphan disease is defined in the US as one that affects fewer than 200,000 at any given time. It is estimated that there are 6000 to 8000 rare diseases in the world today. Because the number of patients afflicted with orphan diseases is so small, drug companies have historically been reluctant to invest money to discover and develop new treatments for them. The dearth of treatments for rare diseases induced Congress to pass the
.jpg)
It’s no secret that pharmaceutical and biotechnology companies are “not in love” with social media. However, whether life sciences company like it or not, social media is beginning to affect human clinical testing with an increasing number of patients demanding access to unapproved experimental drugs to treat life-threatening illnesses. 
While I never was involved in a corporate acquisition or merger, I have many friends who have lived through them and based on their experiences it is a never a “pretty sight.” Merger aftermaths usually feature massive layoffs, executive management disputes and turf wars and corporate culture clashes tha occur when two workforces are forced to merge as one. However, sometimes mergers may be a good thing for struggling companies. To that end, Pfizer 
For the past 10 years or so, I have been providing career counseling and development seminars and workshops for life scientists. In the early years, students, postdocs and a smattering of faculty members would attend to learn about industry trends, the job market and more recently, alternate careers for PhDs and postdoctoral fellows. However, over the last few years, a disturbing trend has emerged—the lack of .jpg)
Cliff Mintz, 
It’s no secret that major pharmaceutical companies are .jpg)
I just learned from Diego Pineda who runs the 
After yesterday's post about career planning for life scientists, one of my soon to be former students in the Fundamentals of Bioscience Program aptly pointed out that my readers might have benefitted more if I had, in fact, offered information about alternate career possibilities for bioscientists. I don't want the student to get too overconfident but I had the same thought immediately after I uploaded the post. 
Yesterday, I gave a lecture entitled “Alternate Careers: Taking the Road Less Traveled” to over 100 members of the University of Pennsylvania’s Biomedical Graduate Student Association. As always, there were many good questions and comments during and after the presentation. Some of the career anecdotes offered by several of the students reminded me of a conversation that I had several weeks ago with one of my Fundamentals of Bioscience students—I teach a Product Development and Regulatory Affairs course in the program—who refreshed my memory about a typical graduate student approach to career development and job searching. “We don’t think about jobs or our careers until we begin writing our PhD theses” she said. “Until then, our advisers don’t talk about careers or jobs and only bring it up because our funding will run out” she added. Admittedly, I had forgotten this because so many years have passed since my graduate student days. That said, it forced me to consider how much the life sciences job market has changed since I was graduate student and how vitally important it is for today’s graduate students to think about and possibly explore different career options throughout the course of their graduate training..jpg)
While I was at the Experimental Biology meeting in New Orleans, LA this past week I presented a seminar entitled “Using Social Media For Career Development in the Life Sciences.” This was the first time that I presented this talk, and was expecting a large turn out given the popularity of Facebook and more recently Twitter, a microblogging platform. Much to my surprise only 15 students showed up for the talk—many of whom hadn’t heard of Twitter and were only vaguely familiar with Facebook. Luckily, a few attendees had Facebook profiles and one or two were on Twitter so the talk wasn't a complete bust. Nevertheless, the lack of interest in this talk was extremely puzzling to me—my other seminars, “Interviewing Tips” and “Alternate Careers for PhDs” were very well attended and I was booked solid for one-on-one resume critiquing sessions during the five days I was in New Orleans.
Since 2007, approximately 80,000 pharmaceutical jobs have been eliminated. The recent consolidation in the industry, e.g., Merck-Schering, Pfizer-Wyeth and Roche-Genentech suggests that many more life sciences jobs will be lost over the next year or so. Typically, to avoid law suits and possible discrimination claims, most companies will layoff a mixture of experienced and entry level employees that cover the racial, religious and age spectra. For those of you who may not know, Americans who are 40 and older constitute a “protected class of employees.” In other words, companies that layoff employees cannot disproportionately give pink slips to employees 40 years of age or older. This law was enacted because older employees typically have higher salaries and have accrued more benefits and vacation time than their more junior counterparts and eliminating them can drastically cut costs. While most companies are careful to layoff a mixture of junior and senior employees during large layoffs, a quick perusal of the demographics of employees who lose their jobs reveals that many of them are older, more experienced workers. Sacrificing a few entry level employees (to prevent any red flags) is worth it to the accountants who charged with cutting costs and orchestrating large corporate layoffs..jpg)
Over the past ten years or so, pundits have been warning that the US is losing its competitive edge and that it is no longer the world’s leading nation when it comes to innovation in science and technology. Measuring national competitiveness and innovation is very tricky business and until now, most of evidence to support these claims has been anecdotal. According to an .jpg)
Twitter, the microblogging platform, is the current rage in social media. According to 
Did you know that the top ten pharmaceutical companies in the world spent close to $50 billion dollars last year on R&D? That sum could be used to purchase the entire US biotechnology industry except for the five largest companies—Genentech, Amgen, Gilead Genzyme and Celgene. Further, pharma’s R&D budget is about 4 times the R&D budget of all of the US biotechnology companies combined. According to a.jpg)
Like it or not, the best way to land a new job whether or not there is a recession is to network. While career counselors and recruiters trumpet the virtues of networking to job seekers, many people really don't understand what it is or how to do it correctly. I found an
Targanta Therapeutics, a Cambridge, MA-based biopharmaceutical company, announced that it 
Online career sites like 
I just returned from my career development sojourn at this year’s FASEB meeting in San Diego, CA. Not surprisingly, all of my sessions were well attended. In fact, attendance at many of the presentations was standing room only. Again, this was not terribly surprising because the job market for graduate students and postdoctoral fellows for the last 5 years has been dismal. However, in contrast with past years, there was a noticeable and palpable difference in the attitudes of many of the students and postdocs who attended the sessions. In previous years, many career development participants seemed resigned to the possibility of a “jobless future”. However, this year there was a small but vocal group of participants who openly expressed their anger and resentment at the possibility of not finding a job after completing their training. I think that many graduate students and postdoctoral fellows have begun to realize that they are being exploited by a fundamentally flawed academic system and that they are “not going to take it anymore.”
I am sitting in Newark Airport waiting for my flight to San Diego which, not surprisingly, has been delayed for about 2 hours. As you might have guessed from the title of this post, I am on my way to the 2008 FASEB Career Development Symposium which is run every year at the annual FASEB meeting. 
Many people think that organizing a job search requires little more than quickly throwing together a resume, applying for online jobs or answering print ads and then kicking back to wait for responses from prospective employers. While this scenario may have been accurate 10 years ago– when jobs were abundant and the economy was humming– it is no longer the case. In fact, the current science job market may be one of the most challenging in the past 20 years or so. This is likely due to shrinking government research spending, contraction of the pharmaceutical and biotechnology industries and the possibility that the American economy is slipping into recession. Nevertheless, there are still available jobs out there. But, in contrast with the past few years, getting them will require a carefully planned and well orchestrated job search..jpg)
downward turn. Even the recession-proof pharmaceutical industry has taken a huge beating over the past year or so– and things seem to be getting worse! The biotechnology industry, which is highly dependent upon venture capital and private equity to remain healthy, is also trending downward and will be hit hard if the economy slides into recession. To make matters worse, the US Department of Labor recently released figures which showed projected growth (for 2006 to 2016) for the fastest-growing occupations in America (see below). Not surprisingly, scientists–industrial or academic– did not make the top 20 list.
In the 